Autoimmune Disease Series--
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by aberrant immune system activation, multi-organ involvement, and autoantibody production. Its etiology involves multifactorial contributions from genetic, environmental, and hormonal factors. Core pathological mechanisms include dysregulated activation of B cells leading to autoantibody production, T cell dysfunction, aberrant activation of interferon signaling pathways, and complement system dysregulation. Conventional therapies rely on glucocorticoids and immunosuppressants but carry risks of infection and organ toxicity, underscoring the need for targeted precision therapies.
Recent advances in SLE drug development focus on modulating key immune checkpoints. Belimumab, the first FDA-approved B cell activating factor (BAFF) inhibitor, blocks BAFF/APRIL signaling to suppress B cell maturation. Telitacicept, a recombinant fusion protein, neutralizes both BAFF and a proliferation-inducing ligand (APRIL), enhancing B cell depletion. Anifrolumab targets the type I interferon receptor, blocking excessive interferon signaling activation. JAK inhibitors such as baricitinib regulate T cell and plasma cell functions by inhibiting the JAK-STAT pathway. Upadacitinib, a selective JAK1 inhibitor, further optimizes efficacy-safety profiles. Emerging approaches include belimumab's new indication targeting complement C1s and CAR-T cell therapy demonstrating promise in refractory SLE, marking a shift from single-target to multi-pathway combination strategies.
CUSABIO specializes in providing high-quality research tools including proteins, antibodies, and ELISA kits. We have curated a series of popular SLE research targets and related reagents for scientific investigators:
Systemic lupus erythematosus Drug Targets in Development:
Systemic lupus erythematosus Drug Targets Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized CD22 at 2 μg/ml can bind Anti-CD22 rabbit monoclonal antibody, the EC50 of human CD22 protein is 4.034-4.800 ng/ml.
Human CD40 protein hFc tag (CSB-MP004936HU1) captured on COOH chip can bind Human CD40L protein hFc and Flag tag (CSB-MP004937HU3) with an affinity constant of 2.06 nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized CD40L at 2 μg/ml can bind Anti- CD40L Rabbit Monoclonal Antibody(CSB-RA156386A0HU), the EC50 is 2.353-3.232 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized Human CD79A at 2 μg/ml can bind Anti-CD79A recombinant antibody(CSB-RA004957MA1HU). The EC50 is 1.521-1.700 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized Human CLEC4C at 2μg/mL can bind Anti-CLEC4C recombinant antibody(CSB-RA855470MA1HU)，the EC50 is 7.658-12.99 ng/mL.
-AC1.jpg)
Measured by its binding ability in a functional ELISA. Immobilized Human IL17A at 2 μg/ml can bind Anti-IL17A recombinant antibody (CSB-RA624104MA1HU), the EC50 is 1.818-2.170 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized Human IL2RA(CSB-MP011649HU3) at 2μg/mL can bind Human IL2，the EC50 is 0.4992 to 0.6269 ng/mL.
The ED50 as determined by the dose-dependent stimulation of the proliferation of human TF-1 cells is 58 - 295 pg/mL.
